Development, Validation, and Comparison of Two Mass Spectrometry Methods (LC-MS/HRMS and LC-MS/MS) for the Quantification of Rituximab in Human Plasma

Rituximab is a chimeric immunoglobulin G1-kappa (IgG1κ) antibody targeting the CD20 antigen on B-lymphocytes. Its applications are various, such as for the treatment of chronic lymphoid leukemia or non-Hodgkin’s lymphoma in oncology, and it can also be used in the treatment of certain autoimmune dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Millet, Aurélien, Khoudour, Nihel, Lebert, Dorothée, Machon, Christelle, Terrier, Benjamin, Blanchet, Benoit, Guitton, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961417/
https://www.ncbi.nlm.nih.gov/pubmed/33806585
http://dx.doi.org/10.3390/molecules26051383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961417/
https://www.ncbi.nlm.nih.gov/pubmed/33806585
http://dx.doi.org/10.3390/molecules26051383

Ejemplares similares